Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA

Liu, Wenyang; Li, Yifei; Tang, Yuan; Song, Qianqian; Wang, Jingjing; Li, Ning; Chen, Silin; Shi, Jiachen; Wang, Shulian; Li, Yexiong; Jiao, Yuchen; Zeng, Yi‐Xin; Jin, Jing

doi:10.1016/j.ebiom.2022.103945

Cited by 34 publications

(89 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four studies applied a tumour informed predefined panel, and ten adopted a tumour agnostic approach. Liu et al investigated multiple ctDNA techniques (22). All studies in this review only included patients with locally advanced rectal cancer (LARC).…”

Section: Resultsmentioning

confidence: 99%

“…Liu et al. investigated multiple ctDNA techniques ( 22 ). All studies in this review only included patients with locally advanced rectal cancer (LARC).…”

Section: Resultsmentioning

confidence: 99%

“…Therefore, in recent years, more and more studies utilising techniques that can specifically detect ctDNA have increasingly been described (22,25,(28)(29)(30)(31)(32)(33)(34)(35). The largest study conducted so far by Tie et al, including 159 patients with LARC, has demonstrated that ctDNA status could be used to classify groups as very high and low risk for recurrence (25).…”

Section: Ctdna and Treatment Outcomes In Rectal Cancer (Cfdna Concent...mentioning

confidence: 99%

See 2 more Smart Citations

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses

et al. 2023

View full text Add to dashboard Cite

BackgroundCirculating tumour DNA (ctDNA) has been established as a promising (prognostic) biomarker with the potential to personalise treatment in cancer patients. The objective of this systematic review is to provide an overview of the current literature and the future perspectives of ctDNA in non-metastatic rectal cancer.MethodsA comprehensive search for studies published prior to the 4th of October 2022 was conducted in Embase, Medline, Cochrane, Google scholar, and Web of Science. Only peer-reviewed original articles and ongoing clinical trials investigating the association between ctDNA and oncological outcomes in non-metastatic rectal cancer patients were included. Meta-analyses were performed to pool hazard ratios (HR) for recurrence-free survival (RFS).ResultsA total of 291 unique records were screened, of which 261 were original publications and 30 ongoing trials. Nineteen original publications were reviewed and discussed, of which seven provided sufficient data for meta-analyses on the association between the presence of post-treatment ctDNA and RFS. Results of the meta-analyses demonstrated that ctDNA analysis can be used to stratify patients into very high and low risk groups for recurrence, especially when detected after neoadjuvant treatment (HR for RFS: 9.3 [4.6 – 18.8]) and after surgery (HR for RFS: 15.5 [8.2 – 29.3]). Studies investigated different types of assays and used various techniques for the detection and quantification of ctDNA.ConclusionsThis literature overview and meta-analyses provide evidence for the strong association between ctDNA and recurrent disease. Future research should focus on the feasibility of ctDNA-guided treatment and follow-up strategies in rectal cancer. A blueprint for agreed-upon timing, preprocessing, and assay techniques is needed to empower adaptation of ctDNA into daily practice.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Liu et al. investigated multiple ctDNA techniques ( 22 ). All studies in this review only included patients with locally advanced rectal cancer (LARC).…”

Section: Resultsmentioning

confidence: 99%

Section: Ctdna and Treatment Outcomes In Rectal Cancer (Cfdna Concent...mentioning

confidence: 99%

See 1 more Smart Citation

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses

et al. 2023

View full text Add to dashboard Cite

show abstract

“…While higher levels of ctDNA at baseline are not reliably prognostic of response, persistent levels of cfDNA/ctDNA detected during and after NAT or prior to surgery correlate with shortened time to disease recurrence, and has given rise to the concept of utilizing ctDNA as a biomarker of minimal metastatic disease (MMD) [36,37,48,56,57,60,64]. Correlations between detectable ctDNA post-NAT and mTRG further point to the practicability of combining ctDNA with image-based monitoring strategies [56,59,60,67].…”

Section: Discussionmentioning

confidence: 99%

“…Liu et al examined the utility of three different strategies for profiling cfDNA in 60 patients with LARC patients neoadjuvant therapy (NAT) [64]. The first was a personalized assay that employed Mutation Capsule technology to profile up to 22 tumor-informed somatic mutations [65].…”

Section: Ctdna Monitoring Beyond Mutationsmentioning

confidence: 99%

A Review of Circulating Tumor DNA as a Biomarker Guide for Total Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer

Yahya

Baber

Nabavizadeh

et al. 2023

J Gastrointest Canc

View full text Add to dashboard Cite

Purpose Non-operative management of patients with locally advanced rectal cancer (LARC) is emerging as a popular approach for patients that have no evidence of disease following neoadjuvant therapy. However, high rates of local recurrence or distant metastases have highlighted the urgent need for robust biomarker strategies to aid clinical management of these patients. Methods This review summarizes recent advances in the utility of cell-free (cf) and circulating tumor (ct) DNA as potential biomarkers to help guide individualized non-operative management strategies for LARC patients receiving neoadjuvant therapy. Results Liquid biopsies and the detection of cfDNA/ctDNA is an emerging technology with the potential to provide a non-invasive approach to monitor disease response and improve the identification of patients with LARC that would best benefit from non-operative management. Conclusions Substantial work is still needed before cfDNA/ctDNA monitoring can be widely adopted in the clinical setting. Studies reviewed herein highlight several areas of opportunity for improving the effectiveness and utility of cfDNA/ctDNA for managing patients with LARC.

show abstract

Role of miRNAs in breast cancer development and progression: Current research

Kumar,

Ranga

2024

BioFactors

View full text Add to dashboard Cite

Breast cancer, a complex and heterogeneous ailment impacting numerous women worldwide, persists as a prominent cause of cancer‐related fatalities. MicroRNAs (miRNAs), small non‐coding RNAs, have garnered significant attention for their involvement in breast cancer's progression. These molecules post‐transcriptionally regulate gene expression, influencing crucial cellular processes including proliferation, differentiation, and apoptosis. This review provides an overview of the current research on the role of miRNAs in breast cancer. It discusses the role of miRNAs in breast cancer, including the different subtypes of breast cancer, their molecular characteristics, and the mechanisms by which miRNAs regulate gene expression in breast cancer cells. Additionally, the review highlights recent studies identifying specific miRNAs that are dysregulated in breast cancer and their potential use as diagnostic and prognostic biomarkers. Furthermore, the review explores the therapeutic potential of miRNAs in breast cancer treatment. Preclinical studies have shown the effectiveness of miRNA‐based therapies, such as antagomir and miRNA mimic therapies, in inhibiting tumor growth and metastasis. Emerging areas, including the application of artificial intelligence (AI) to advance miRNA research and the “One Health” approach that integrates human and animal cancer insights, are also discussed. However, challenges remain before these therapies can be fully translated into clinical practice. In conclusion, this review emphasizes the significance of miRNAs in breast cancer research and their potential as innovative diagnostic and therapeutic tools. A deeper understanding of miRNA dysregulation in breast cancer is essential for their successful application in clinical settings. With continued research, miRNA‐based approaches hold promise for improving patient outcomes in this devastating disease.

show abstract

Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA

Cited by 34 publications

References 33 publications

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses

A Review of Circulating Tumor DNA as a Biomarker Guide for Total Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer

Role of miRNAs in breast cancer development and progression: Current research

Contact Info

Product

Resources

About